AGM Statement and Proxy Voting Results (0909I)
June 08 2011 - 8:12AM
UK Regulatory
TIDMATD
RNS Number : 0909I
Asterand PLC
08 June 2011
For Immediate Release 8 June 2011
Asterand plc
AGM Statement and Proxy Voting Results
Asterand plc (LSE: ATD), a leading provider of human tissue and
human tissue-based research services to pharmaceutical and
biotechnology companies engaged in drug discovery research, today
held its Annual General Meeting ("AGM") at 10:00 (BST), in
London.
During the meeting, Mr. Martyn Coombs, Asterand's CEO, provided
an overview of the Company's business and future strategy and,
Robert Coleman PhD DSc, a leading drug discovery consultant, gave a
short presentation titled "The use of human tissue".
www.asterand.com.
Also at the AGM, all of the resolutions set out in the Notice of
Meeting sent to Shareholders as part of the Report and Financial
Statements for the year ended 31 December 2010 were passed, save
for resolution 10.
Proxy votes on the resolutions were as follows:
For
(including
Ordinary Resolutions discretionary) Against Vote Withheld
---- ------------------------- ---------------- ----------- --------------
To receive and adopt the
Report and
1. Accounts 58,508,772 512 240
---- ------------------------- ---------------- ----------- --------------
To receive and adopt the
Directors' report on
2. remuneration 47,298,921 11,190,067 20,536
---- ------------------------- ---------------- ----------- --------------
To re-elect Jill Force
3. as a Director 58,489,976 9,308 10,240
---- ------------------------- ---------------- ----------- --------------
To re-elect Robert
4. Salisbury as a Director 58,485,227 9,308 14,989
---- ------------------------- ---------------- ----------- --------------
To re-elect Jonathan
5. Fleming as a Director 47,313,428 1,751,834 9,444,262
---- ------------------------- ---------------- ----------- --------------
To re-appoint
PricewaterhouseCoopers
6. LLP as Auditors 58,502,583 0 6,941
---- ------------------------- ---------------- ----------- --------------
To amend the Company's
7. articles of association 58,490,535 4,000 14,989
---- ------------------------- ---------------- ----------- --------------
That the Company's
memorandum of
association, being
deemed to form part of
the Articles, be
8. amended 58,490,535 4,000 14,989
---- ------------------------- ---------------- ----------- --------------
Issue of shares by the
9. Directors 42,738,770 15,751,514 19,240
---- ------------------------- ---------------- ----------- --------------
Disapplication of
10. pre-emption rights 42,738,258 15,747,277 23,989
---- ------------------------- ---------------- ----------- --------------
Notice of general
11. meetings 58,499,284 10,000 240
---- ------------------------- ---------------- ----------- --------------
- Ends -
Contacts:
Asterand plc
Martyn Coombs, Chief Executive Tel: + 44 (0) 1763 211 600 / + 1 (313)
Officer 263-0960
John Stchur, Chief Financial As above
Officer
Buchanan Communications
Lisa Baderoon / Mark Court Tel: +44 (0) 20 7466 5000
/
Isabel Podda
Daniel Stewart & Company plc
Antony Legge Tel: +44 (0) 20 7776 6566
About ASTERAND
Asterand plc is a leading supplier of high quality human tissue
and tissue-based services. Our comprehensive approach to human
tissue and research services offers pharmaceutical, biotech and
diagnostic companies the unique opportunity to have one company
meet all of their human biomaterial needs along the continuum of
drug discovery and development. Our mission is to accelerate target
discovery and compound validation and enable pharmaceutical and
biotechnology companies to take safer and more effective drugs into
the market.
For more information, go to www.Asterand.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMFPMJTMBMMBLB
Bioseek (LSE:ATD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Jul 2023 to Jul 2024
